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Background. Aging may be accompanied by a low grade chronic up-regulation of inflammatory mediators. A variety of
endogenous locally released mediators as well as inflammatory cells have been reported in the human oral cavity. The aim of
this investigation was to determine the presence of different classes of inflammatory mediators in human saliva and correlate
the levels with age. Methodology and Principal Findings. Unstimulated whole buccal salivary samples were obtained in the
morning from 94 healthy volunteers within 30 minutes after waking. None of the participants had taken aspirin in the week
prior to the saliva collection. Lysozyme activity, eicosanoid levels (prostaglandin E2 and leukotriene B4) and MMP-9 activity
were measured. The antimicrobial activity (lysozyme activity) was not correlated with age whereas PGE2 levels were markedly
correlated with age (r=0.29; P,0.05; n=56). Saliva from healthy subjects (#40 years) compared with data derived from older
volunteers (.40 years) demonstrated a significant increase in the mean values for PGE2 and MMP-9 activity with age. In
addition, significant correlations were observed between LTB4 and PGE2 (r=0.28; P,0.05; n=56) and between LTB4 levels and
MMP-9 activity in smokers (r=0.78; P,0.001; n=15). Conclusions/Significance. The presence of significant levels and
activity of inflammatory mediators in saliva suggests that the oral cavity of healthy subjects may be in a constant low state of
inflammation associated with age.
Citation: Ba ¨ck M, Hlawaty H, Labat C, Michel J-B, Brink C (2007) The Oral Cavity and Age: A Site of Chronic Inflammation? PLoS ONE 2(12): e1351.
doi:10.1371/journal.pone.0001351
INTRODUCTION
The cardinal sign of inflammation is the presence of endogenous
locally released mediators at the site of a perturbation. This initial
event is followed by a more chronic condition characterized by a
recruitment and accumulation of inflammatory cells associated
with local proteolytic and oxidative activities at the site of insult.
There is sufficient information suggesting that aging is accompa-
nied by a low grade chronic up-regulation of inflammatory
mediators [1]. Such underlying modifications may be responsible
for, or contribute to, the evolution of various age-dependent
disease conditions, such as, atherosclerosis.
In the oral cavity of normal healthy subjects, the presence of a
spectrum of bacterial populations [2] and a number of leukocytes,
especially polymorphonuclear leukocytes (PMNs) [3,4] have been
reported. In addition to these observations, human saliva contains
several factors which can be classified and profiled according to
their principal actions [5]. Lysozyme is known to have
antimicrobial activities, whereas eicosanoids (prostaglandins and
leukotrienes) are thought to have pro-inflammatory actions and
matrix metalloproteinases (MMPs) [6] exhibit proteolytic effects at
the site of inflammation.
In spite of the fact that these mediators have such remarkably
diverse activities, there have been few attempts to describe
correlations among them. Generally, most studies have simply
targeted the role of a particular mediator as a marker of a disease
condition [7]. However, the profiles of inflammatory cells and
mediators are known to be altered during the progression of a
disease and may explain the controversy that frequently arises
among studies concerning similar patient cohorts [1]. Although
the local inflammatory environment of the oral cavity has been
reported to be markedly exacerbated in diseased subjects [6,8–11],
the phenomenon, albeit less intense, may also be present in healthy
subjects of different ages. While there is considerable work
published on disease in the oral cavity, there is little information
available to elucidate the low chronic inflammatory conditions
that may exist in the oral cavity in normal subjects. Indeed, most
studies in patients have dealt only with the effects of the mediators
of inflammation on acute phenomenon [2,6] and few investiga-
tions have centered on the side effects of inflammatory mediators
when the onset is slow but persistent over a prolonged period
[7,8,11]. This study was undertaken to measure various mediators,
known to be intimately linked to the inflammatory process, in
saliva of healthy subjects at different ages. The principal aim was
to establish the correlations which may exist among the different
classes of mediators and aging with the hypothesis that the oral
cavity may be in a state of low chronic inflammation.
RESULTS
There was considerable variation in the levels of lysozyme and
MMP-9 activities as well as the levels of arachidonic acid
metabolites detected in the human salivary samples under basal
conditions (Table 1). However, the significantly higher levels of
LTB4 compared with PGE2 (Table 1) was consistent in all
subgroups studied (Table 2–4).
The lysozyme activity measured in human saliva was not
correlated with age (Fig 1a; n=94). In contrast, the data presented
in Figure 1 indicate a significant correlation with age for PGE2
(Fig 1b; n=56) with about 2-fold higher salivary levels of PGE2 in
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40 years (Table 2).
In contrast, LTB4 was not significantly correlated with age
(Fig 1c; n=60) and the salivary levels of LTB4 were not
significantly different between older and younger subjects
(Table 2). However, in the younger subjects, LTB4 was
significantly correlated with age, although this may be due to
the presence of outliers (Fig 1c inset; n=33). Furthermore, a
significant (approximately 3-fold) increase in MMP-9 activity was
demonstrated in saliva derived from older (.40 years old)
compared with younger (,40 years) subjects (Table 2).
The results presented in Figure 2 demonstrated significant
correlations between the levels of the eicosanoids PGE2 and LTB4
detected in the human salivary samples (Fig 2a; n=56). Although
none of the mediators were significantly altered in saliva from
smokers compared with non-smokers, the correlation between
LTB4 levels and MMP-9 activity was revealed significant in the
smoking group (Fig 2c, n=15) but not in non-smokers. There
were no significant correlations between the above mentioned
mediators in relation to lysozyme (data not shown).
There was no significant modification in any of the mean values
when the data were adjusted for either sex or smoking (Table 3
and 4). In addition, gelatin zymography demonstrated the
presence of gelatinolytic activities in all saliva samples at apparent
molecular weights of 92 kD and 80 kD corresponding to latent
and active MMP-9, respectively. EDTA but not TrasylolH,
inhibited these gelatinolytic activities (data not shown) supporting
the observation that these effects were related to the MMP profiles.
DISCUSSION
The present study, demonstrating significant correlations between
age and inflammatory mediators of the eicosanoid and MMP
pathways in whole buccal saliva from healthy volunteers, points to
a marked modification of the inflammatory state of the oral cavity
Table 1. Mediator levels and activities in salivary samples from
all subjects.
......................................................................
Women Smokers 52%
22%
N mean6sem (range)
Age (years) 94 3661 (14–76)
Lysozyme activity (mg/ml) 94 108612 (1–821)
PGE2 (pg/ml) 56 242631 (47–1126)
LTB4 (pg/ml) 60 12236170 (105–6686)
pro-MMP-9 (AU) 27 12.0262.49 (0.01–51.65)
MMP-9 (AU) 27 5.3961.14 (0.00–20.01)
n indicates number of subjects studied.
doi:10.1371/journal.pone.0001351.t001
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Table 2. Mediator levels and activities in salivary samples from young (#40 years) and old (.40 years) subjects.
..................................................................................................................................................
Women Smokers #40 years .40 years
48% 59%
21% 25%
n means6sem (range) n means6sem (range)
Age (years) 62 2761 (14–40) 32 5461 (42–76)
Lysozyme activity (mg/ml) 62 119617 (1–821) 32 86614 (5–322)
PGE2 (pg/ml) 30 163617 (59–381) 26 334659* (47–1126)
LTB4 (pg/ml) 33 10036193 (105–4897) 27 15136286 (217–6686)
pro-MMP-9 (AU) 15 6.7661.63 (0.01–20.13) 12 18.5964.66* (0.03–51.65)
MMP-9 (AU) 15 2.8060.91 (0.01–13.52) 12 8.6361.98* (0.00–20.01)
n indicates number of subjects studied and *indicates values significantly different from young subjects (P,0.05).
doi:10.1371/journal.pone.0001351.t002
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Table 3. Mediator levels and activities in salivary samples from non-smokers and smokers.
..................................................................................................................................................
Women Non-smokers Smokers
51% 57%
n means6sem (range) n means6sem (range)
Age (years) 73 3662 (14–76) 21 3863 (21–61)
Lysozyme activity (mg/ml) 73 114614 (1–821) 21 86621 (14–322)
PGE2 (pg/ml) 36 280645 (47–1126) 20 175627 (59–521)
LTB4 (pg/ml) 39 12376228 (100–6686) 21 12246228 (200–4718)
pro-MMP-9 (AU) 12 10.3762.61 (0.01–28.76) 15 13.3464.02 (0.09–51.65)
MMP-9 (AU) 12 5.0161.52 (0.00–18.32) 15 5.6961.70 (0.03–20.01)
n indicates number of subjects studied.
doi:10.1371/journal.pone.0001351.t003
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Saliva and Mediators
PLoS ONE | www.plosone.org 2 December 2007 | Issue 12 | e1351Table 4. Mediator levels and activities in salivary samples from men and women.
..................................................................................................................................................
Smokers Men Women
20% 24%
n means6sem (range) n means6sem (range)
Age (years) 45 3562 (14–67) 49 3762 (14–76)
Lysozyme activity (mg/ml) 45 83611 (4–310) 49 130621 (1–821)
PGE2 (pg/ml) 27 210630 (51 -602) 29 273653 (47–1126)
LTB4 (pg/ml) 28 11506220 (201–4718) 32 13046254 (100–6686)
pro-MMP-9 (AU) 11 9.3962.91 (0.03–28.00) 16 13.8363.71 (0.01–51.65)
MMP-9 (AU) 11 4.3661.57 (0.00–16.53) 16 6.1061.62 (0.01–20.01)
n indicates number of subjects studied.
doi:10.1371/journal.pone.0001351.t004
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Figure 1. Relationship between age and mediators of inflammation in saliva from healthy subjects. Panel a: lysozyme activity, b: PGE2, c: LTB4
(with inset showing #40 years) and d: MMP-9 activity. Diagonal lines are the regression correlations when shown to be significant.
doi:10.1371/journal.pone.0001351.g001
Saliva and Mediators
PLoS ONE | www.plosone.org 3 December 2007 | Issue 12 | e1351associated with age. Furthermore, the data suggest that this age-
related inflammatory response was independent of the innate oral
antimicrobial activity as monitored by lysozyme activity.
Whereas the majority of previous investigations involving
measurements of lysozyme activity in human saliva have dealt
with either the cellular origin [12,13] or the activities monitored in
a variety of disease conditions in the oral cavity [2,7,8,14–16],
there is little conclusive information on the lysozyme activity in
saliva from normal subjects and age. The present data from
healthy volunteers demonstrated that the lysozyme activity was not
correlated with age. In contrast, PGE2 levels and MMP-9 activity
were increased with age. These observations suggest that aging
and inflammation in the oral cavity evolve together, whereas the
antimicrobial activity remains constant. Furthermore, the signif-
icant correlations observed among the eicosanoids and the marked
association between LTB4 and MMP-9 activities in smokers would
also suggest that the mediators of inflammation may originate
from the same cellular source upon stimulation. Since these
mediators are a cardinal sign of inflammation, the results indirectly
suggest that the oral cavity of healthy subjects may be in a state of
chronic inflammation. High levels of PGE2 have been correlated
with periodontal disease [10] and were suggested to predict the
evolution and severity of this disease [17]. One possible
explanation for the results (present report) is that all healthy
subjects without exception have periodontal disease and that
elevated levels of PGE2 were a sign of this condition rather than
age. However, that all healthy subjects have periodontal disease
seems unlikely since Loe [18] elegantly demonstrated that gingival
inflammation was not recognized in healthy subjects until at least
10 days following cessation of all measures of dental cleanliness
and that 2–3 weeks without oral hygiene is necessary to produce
mild inflammation. While no oral examination was performed on
Figure 2. Relationship between different mediators of inflammation in saliva from healthy subjects. Panel a: PGE2 vs. LTB4, b: MMP-9 activity vs.
LTB4, c MMP-9 activity vs. LTB4 in smokers, d: c MMP-9 vs. LTB4 in non-smokers. Diagonal lines are the regression correlations when shown to be
significant.
doi:10.1371/journal.pone.0001351.g002
Saliva and Mediators
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performed basic oral hygienic measures. Unfortunately, there is
little information available addressing gingival status in healthy
subjects at different ages. Although lysozyme activity has not been
correlated with either gingival inflammation [19] or age (this
report), the interpretation that increased levels of PGE2 may be
linked to periodontal disease and/or aging supports the notion that
the oral cavity may be in a state of chronic low inflammation.
The detection of both cyclooxygenase and lipoxygenase
metabolites in human saliva (present study) supports the data
from previous investigations [5,20,21]. These mediators have been
shown to be elevated in diseased subjects [10]. While the latter
report indirectly suggested a relationship between inflammatory
mediators in the oral cavity, the present report established a
significant correlation between PGE2 and LTB4 in saliva from
healthy subjects. The data, in addition, confirm and extend the
observations of a preferential release of lipoxygenase metabolites
in saliva from healthy subjects [7,22] since LTB4 levels were
predominantly detected compared with PGE2 at all ages.
Increased levels of LTB4 have also been reported in gingival
crevicular fluid from patients with periodontal disease and recent
results have now confirmed these observations in the gingival
crevicular fluid of patients with cardiovascular disease [11].
However, the present and previous [23] studies detecting
nanogram levels of leukotrienes suggest that human whole buccal
saliva contains approximately 5–10 fold more lipoxygenase
products compared with the gingival crevicular fluid.
The high concentrations of LTB4 detected in human saliva are
in contrast to the difficulty to detect this lipoxygenase product in
blood and urine samples. The latter findings have been explained
by the notion that LTB4 is thought only to be produced, released
and act locally via cell membrane receptors at the site of the
inflammatory response. Since the principal action of LTB4 is
chemotaxis with a primary target being leukocytes, one would on
this basis expect the oral cavity of healthy subjects to be
overwhelmed with PNMs. However, this is not the case since
healthy subjects are known to have only low levels of PMNs in the
oral cavity [2,3,5]. Therefore, the role of LTB4 at nanogram
concentrations in human saliva, which can be significantly reduced
by lipoxygenase inhibitors [23], is presently difficult to explain.
Nevertheless, a possible speculative explanation may be proposed
based on the previous and the following observations. In the
present study, the saliva was acidified to a pH of approximately 3
during analysis, confirming a resistance of leukotrienes to low pH
[24] and suggesting a possible stability of salivary LTB4 during
gastrointestinal (GI) passage. When saliva is swallowed (about
1.5 liters/24h) there may be sufficient quantities of LTB4 available
to regulate the human GI-tract. This notion is further supported
by the markedly lower ability of isolated human intestinal segments
to convert arachidonic acid to leukotrienes compared with their
production of PGE2 via local expression of the cyclooxygenase
isozymes within the intestinal wall [25]. These observations suggest
that salivary LTB4 may not only have local actions in the oral cavity,
albeit, presently not known, but may also effect and regulate tissues
in the GI-tract. The notion of a possible distant effect for the
substantial quantities of LTB4 detected in the oral cavity is well
within the potential for the capacity of salivary components to
interact with the GI-tract as supported by the effects of smoking on
inflammatory bowel disease [26], potential GI-tract mucosal
protection by salivary derived nitric oxide in patients in intensive
care units [27,28] as well as the enhanced mediator release and
altered ionic conditions in the esophageal mucosal barrier after
stimulation of salivary secretion in patients with gastroesophageal
reflux (GER) disease [29,30]. Along similar lines, night-time GER is
intimately linked to sleep apnea and hypertension [30] during a
period when the swallowing rate and the production of saliva are
markedly reduced. Finally, data from animal models have clearly
linked salivary production of mediators with GI-tract regulation
since sialoadenectomy markedly reduces luminal intestinal levels of
epidermal growth factor in mice [31]. Although each of the complex
conditions cited above may involve a variety of different mecha-
nisms, the point to highlight is that components of saliva may be
implicated in the regulation of the GI-tract. In view of the constant
and considerable locally released quantities of LTB4 in the oral
cavity of healthy human subjects, the concept of lipoxygenase
metabolites acting only locally may have to be re-examined.
MMP-9 constitutes the dominant MMP activity in saliva
[6,9,32], which was confirmed in the present report using similar
gelatinolylic activity assays. However, in contrast to previous
studies, MMP-9 activity was detected also in acidified saliva
(present report). These observations support the notion that
salivary MMP-9 activity may also be a potential mediator distal to
gastric passage. Interestingly, mice with a targeted MMP-9 gene
deletion display reduced extent and severity of bacterial induced
enterocolitis [33]. In the present study, salivary MMP-9 activity
was significantly higher in older subjects, hence reinforcing the
notion of the oral cavity as a site of chronic inflammation
associated with aging. Furthermore, in smokers, but not in non-
smokers, MMP-9 activity was closely correlated to LTB4. Previous
findings on the effects of smoking on leukotriene concentrations
are contradictory with both neutral effects [11] and decreased [34]
oral concentrations having been reported. While no alterations of
LTB4 levels was observed in smokers compared with non-smokers
in the present study, the alteration of the LTB4/MMP-9
correlation in smokers indicate interactions between these two
pathways provoked by smoking.
In conclusion, the present study suggests that the inflammatory
response as monitored by eicosanoid concentrations and MMP-9
activity in saliva is intimately linked with age, whereas the
lysozyme antimicrobial activity may be independent. The presence
of significant levels of these specific mediators of inflammation
suggests that the oral cavity in man is in a constant low state of
inflammation. While there are several mediators which act locally
such as in periodontal disease, the observations cited above and
the data (present report) suggest that there may be salivary factors
acting as distant mediators in the GI-tract.
MATERIALS AND METHODS
Subjects
This study group consisted of 94 healthy subjects (45 men and 49
women), whose ages ranged from 14 years to 76 years and had not
taken aspirin in the week prior to the salivary sample. Included in
these healthy volunteers was a group of 21 healthy smokers (less
than 10 cigarettes/day). All subjects exercised basic measures of
oral hygiene. Written and oral consent were obtained from each
subject prior to the study. A written response from the national
committee stated that this study did not require submission to the
Comite ´ de Protection des Personnes.
Sample collection
Whole buccal saliva was collected from subjects within the first
30 min after waking in the morning. Subjects were either requested
to collect 1 ml samples or individuals were requested to collect a
sample during a 3 min period (16 men and 21 women). Samples
werebroughttothelaboratoryatthebeginningoftheworkday.The
saliva was diluted with de-ionized water (1:4 v/v). The pH was
adjustedtopH3.5–4withaceticacidandheatedfor2 minat100uC.
Saliva and Mediators
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aliquots of 1 ml were stored at 220uC until analysis.
Lysozyme assay
Lysozyme activity was determined spectrophotometrically by
measuring the lysis of a suspension of Micrococcus lysodeikticus
(3 mg/ml) [35]. Standard curves were constructed by incubation
of egg white lysozyme (1 mg/ml) in 1.5 ml of 50 mM potassium
phosphate buffer containing M. lysodeikticus, sodium azide (0.1%),
BSA (1 mg/ml), mixed and incubated at 37uC for 2 h. An aliquot
of 200 ml of each sample was added to 1.8 ml of potassium
phosphate buffer containing the bacterial buffer as indicated. The
pH of this working solution was between 7.1–7.4. Serial dilutions
(nine) were performed and the changes in turbidity were
monitored at a wavelength of 450 nm with potassium phosphate
buffer as blank. A standard curve was plotted as optical density
versus the concentration of lysozyme. The lysozyme activity
detected in the fluids derived from the saliva were estimated from
the standard curves and expressed as mg/ml. Flow rates in healthy
volunteers (men: 0.6860.09 mg/ml/min, n=16 and women:
0.6760.09 mg/ml/min, n=21, were not significantly different).
The lysozyme activities under flow controlled conditions were not
different from data obtained from individuals who collected 1 ml
of saliva. The mediator release and MMP-9 activities measured
were also independent of flow.
Eicosanoid assays
The levels of the different metabolites of arachidonic acid were
determined using enzyme-immunoassays kits for prostaglandin E2
(PGE2) and leukotriene B4 (LTB4: Cayman Chemical Co USA).
Measurements were made by following the instructions provided
in the commercially available kits and were performed on the
salivary fluids which had been diluted with water, adjusted to low
pH and heated.
MMP-9 gelatin zymographic assays
Gelatinolytic activities of pro-MMP-9 and MMP-9 were measured
as previously described [36]. Briefly, the 20 ml of samples were
mixed with loading buffer (50 mM TRIS–HCl, pH 6.8, 0.1%
glycerol, 2% SDS, 0.5 mg/ml bromophenol blue). The electro-
phoresis was performed in 10 % polyacrylamide gels containing
2.5 mg/ml of gelatine (type IV) in TRIS-base-glycine buffer
(0.124 M TRIS, 0.95 M glycine, 0.01% SDS) at 200V during
1 hour. Then, the gels were soaked two times for 30 min in 2.5%
Triton X-100 at room temperature followed by brief rinse in
distilled water. The incubation with 50 mM TRIS-HCl, pH 7.8,
10 mM CaCl2 buffer was performed for 19 h at 37uC. Gels were
stained with Coomassie Brilliant Blue buffer (0.5% Coomassie
Brilliant Blue R-250, 10% propanol, 5% acetic acid) on a shaker at
room temperature, destained in 10% acetic acid, 30% ethanol (v/
v) during 10 min and stored in 10% acetic acid solution (v/v). The
inhibition profile of the gelatinolytic activities were performed by
incubating the gels with 10 mM EDTA or 50 mg/ml TrasylolH
(serine protease inhibitor).
Calculations and Statistical analysis
All results are means6SEM. The pro-MMP-9 and MMP-9
activities were estimated from the two major bands obtained in the
zymographic assays when judged to be in a linear range which
corresponded to the gelatinolytic migration activity of a previously
published standard [36]. This MMP-like activity was expressed in
arbitrary units (AU). Statistical analysis for comparisons between
age groups was performed by one-factor ANOVA, with post hoc
comparisons made by Bonferroni-corrected paired tests. Linear
associations were determined as Pearson’s correlation coefficients
(r). Multivariate analysis was also performed for investigating the
associations between the measured parameters and a value of
P,0.05 was taken as an indication of significance.
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